布罗达鲁单抗在3期随机对照试验中改善银屑病瘙痒及其他症状
三项3期随机对照试验(AMAGINE-1/-2/-3)评估布罗达鲁单抗治疗中重度银屑病,使用银屑病症状量表(PSI)评估皮损症状。布罗达鲁单抗较安慰剂从第2周至第12周显著改善PSI总分和瘙痒评分(P<0.001),且210 mg每2周方案较乌司奴单抗起效更快,持续治疗52周后瘙痒应答优于乌司奴单抗。
要点
- 布罗达鲁单抗较安慰剂从第2周至第12周显著改善PSI总分和瘙痒评分,P<0.001。
- AMAGINE-2/-3中,布罗达鲁单抗210 mg每2周第2周PSI总分和瘙痒应答率分别为22.1%和36.4%,乌司奴单抗分别为6.9%和17.1%。
- 持续治疗52周后,布罗达鲁单抗的瘙痒应答优于乌司奴单抗。
核心结论
- 布罗达鲁单抗较安慰剂和乌司奴单抗快速、显著改善PSI评估的症状,包括瘙痒。
研究设计与样本
- 三项随机对照3期试验(AMAGINE-1/-2/-3),患者随机接受布罗达鲁单抗140或210 mg每2周、安慰剂(AMAGINE-1/-2/-3)或乌司奴单抗(AMAGINE-2/-3),12周诱导期后维持治疗至52周。
主要发现
- AMAGINE-1/-2/-3中,布罗达鲁单抗较安慰剂从第2周至第12周改善PSI总分和瘙痒评分,P<0.001。
- AMAGINE-2/-3中,布罗达鲁单抗210 mg每2周第2周PSI总分应答率为22.1%,瘙痒应答率为36.4%;乌司奴单抗分别为6.9%和17.1%。
- 持续治疗52周后,布罗达鲁单抗的瘙痒应答优于乌司奴单抗。
关键数值与推荐
- PSI应答者定义为第12周平均每周总分≤8且无单项评分>1。
- PSI各项(瘙痒、灼烧、刺痛、疼痛、发红、脱屑、皲裂和脱皮)按过去24小时严重程度0(完全不严重)至4(非常严重)评分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with psoriasis have lesional symptoms, including itch, which can reduce quality of life. The efficacy and safety of brodalumab, an interleukin-17 receptor A antagonist, in treating moderate-to-severe psoriasis have been reported in three randomized, controlled, phase 3 trials (AMAGINE-1/-2/-3). OBJECTIVE: The effect of brodalumab on lesional symptoms was assessed using the psoriasis symptom inventory (PSI), a validated patient-reported instrument. METHODS: Patients were randomized to receive brodalumab (140 or 210 mg every 2 weeks [Q2W]), placebo (AMAGINE-1/-2/-3), or ustekinumab (AMAGINE-2/-3) during a 12-week induction phase, followed by a maintenance phase through week 52. Patients electronically rated the severity of PSI items (itch, burning, stinging, pain, redness, scaling, cracking and flaking) during the previous 24 h on a scale of 0 (not at all severe) to 4 (very severe). At each visit, the PSI total score responder status was assessed, with responders defined as having an average weekly total inventory score ≤8 with no item score >1 at week 12. RESULTS: Across AMAGINE-1/-2/-3, brodalumab was associated with improvements in PSI total scores and itch scores vs. placebo from week 2 through week 12 (P < 0.001 in both domains). In AMAGINE-2/-3, brodalumab 210 mg Q2W demonstrated faster onset of PSI total score and itch responses (week 2, 22.1% and 36.4%, respectively) vs. ustekinumab (week 2, 6.9% and 17.1%, respectively) and was associated with improved itch responses vs. ustekinumab after 52 weeks of constant treatment. CONCLUSION: Brodalumab demonstrated rapid, robust improvements in symptoms assessed by the PSI, including itch, vs. placebo and ustekinumab.
引用
- Gottlieb AB, Gordon K, Hsu S, et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2018. PMID: 29512200. doi:10.1111/jdv.14913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。